ABSTRACT -The effects of oxiracetam on the reduction of brain metabolism induced by focal cerebral ischemia were investigated by measuring local cerebral glucose uti lization (LCGU) in rats 24 hr after left middle cerebral artery occlusion. Focal cere bral ischemia reduced LCGU in the entire ipsilateral cortex, the greatest reduction being in the lateral parts of the frontoparietal cortex. LCGU was slightly reduced in the contralateral cortex; this reduction was considered to be caused by diaschisis. Ox iracetam was administered intraperitoneally for 3 days prior to middle cerebral artery occlusion. In the ipsilateral cortex, LCGU reduction was minimized in the ischemic center areas by oxiracetam at a dose of 400 mg/kg and in more extensive areas, by a dose of 800 mg/kg. Moreover, oxiracetam at a dose of 800 mg/kg enhanced metabo lism impaired by diaschisis in the caudal areas of the contralateral cortex. These find ings suggest that oxiracetam minimizes the reduction of brain function induced by ischemia and may therefore be useful in the treatment of cerebrovascular disease.
The pharmacological actions of oxiracetam are similar to those of other pyrrolidone de rivatives, including piracetam, aniracetam and pramiracetam. Oxiracetam and other pyrroli done derivatives have been reported to im prove memory and learning ability in normal animals (1) and to prevent amnesia and the decrease in brain acetylcholine level induced by scopolamine and electroshock in rats (2 4) . Oxiracetam and piracetam stimulate high affinity choline uptake in the rat hippocampus (5) . Thus, the effects of pyrrolidone deriva tives may be related to the enhancement of brain cholinergic mechanisms. In addition, ox iracetam and other pyrrolidone derivatives have been shown to augment hippocampal long-term potentiation in rats (6) and guinea pigs (7, 8) . These investigations suggest that pyrrolidone derivatives enhance cerebral func tion in normal brain and protect it in impaired brain. Since we have recently found that ox iracetam protects rats and mice against cere bral hypoxia, we expected to find that ox iracetam had protective effects against cere bral ischemia in this experiment.
Focal cerebral ischemia induced by middle cerebral artery (MCA) occlusion (9) is a use ful model (9, 10) for studying ischemic brain damage, as well as cerebral blood flow (11, 12) , energy metabolism (13) , and neurotrans mitters (14, 15) . Sokoloff (16) showed that cerebral functional activity was closely coupled to energy metabolism, especially glucose con sumption. In this study, we investigated whether the measurement of local cerebral glucose utilization (LCGU) in the ischemic brain could be useful for evaluating the dis tribution and degree of ischemic damage in the rat neocortex. In addition, we examined the effects of oxiracetam on the reduction of LCGU in MCA-occluded rats. Tables 1 and 2 . The cortex in each hemisphere was divided into 2-4 areas. 1: medial area in the dorsal part, 2: lateral area in the dorsal part, 3: upper area in the lateral part, 4: lower area in the lateral part.
MATERIALS AND METHODS
Male Wistar rats (200-300g) were used. They were anesthetized with 2% halothane during occlusion of the left MCA. MCA occlusion was performed according to the method of Tamura et al. (9) . The temporal muscle and the zygoma were removed, and the jaw was retracted to allow access to the in fratemporal skull. A craniectomy, anterior to the foramen ovale, was performed with a mi crodrill, and the dura and arachnoid were di vided. The stem of the proximal left MCA was occluded by electrocoagulation with fine tipped bipolar forceps under a surgical micro scope. In sham-operated rats, the arachnoid surrounding the MCA was divided, but the MCA was not occluded.
Oxiracetam, dissolved in saline, was intra peritoneally administered once a day, at a dose of 400 or 800 mg/kg, for 3 days prior to MCA occlusion. Control rats were injected with saline according to the same schedule. MCA occlusions were performed 1 hr after the last administration of oxiracetam, and the rats were fasted for the following 24 hr, except for receiving water, to stabilize the plasma glucose concentration.
LCGU was determined by the method of Sokoloff et al. (17) . The rats were anesthe tized with halothane and cannulated via the femoral artery and vein; the animals were allowed to awake from the anesthesia, and the lower half of their bodies was immobilized with a loose-fitting plaster cast on a lead block.
Measurement of LCGU began 24 hr after MCA occlusion. 2-Deoxy-[14C]glucose (20 30 ,u Ci/rat) in saline was injected intravenously as a bolus. Arterial blood pressure and arterial blood gases were measured immediately be fore the isotope injection. Following this injec tion, timed arterial blood samples were taken over a 45-min period to determine plasma glu cose and 14C concentration. Plasma glucose and 14C concentration were measured by the peroxidase method and by a liquid scintillation counter (Beckman LS 9000), respectively.
The rats were decapitated 45 min later, and the brains were immediately removed and frozen in freon-12 at -40°C. Coronal sections, 20,um in thickness, were prepared in a cryos tat at -20°C. These sections were placed on glass coverslips, dried on a hot plate at 60°C, and exposed for 7 days to X-ray film (Kodak SB-5) together with a calibrated 14C-methyl methacrylate standard in an X-ray cassette. The optical densities of the regions in the autoradiographs were measured; these meas urements were converted into LCGU using the equation of Sokoloff et al. (17) . The autoradiographs were transformed into quan titative color-coded LCGU maps by a compu ter system (Unigraphy UHG-101, Unique Medical). LCGU measurements were limited to the MCA territorial area in the cerebral cortex. Coronal sections were taken from 6 levels in the brain, and the cortex in each hemisphere was divided into 2 4 areas ( Fig.  1 ). LCGU was calculated in 21 areas in each hemisphere.
Student's two-tailed t-test was used for sta tistical analyses. Tables 1 and 2 show LCGU values in the cortex ipsilateral and contralateral to the occlusion, respectively.
Effects of MCA occlusion on LCGU
In the sham-operated group, LCGU values were within normal ranges, as reported by Sokoloff et al. (17) ; there was no difference between LCGU values in the ipsilateral and contralateral cortex in this group (Tables 1  and 2 ).
In the MCA-occluded group, LCGU values were significantly reduced in all areas of the ipsilateral cortex compared with the sham operated group (Table 1 ). The greatest reduc tions (< 20,umol/100 g/min) were observed in A:3, B:3 and 4 and C:4, which were in the lateral part of the frontoparietal cortex; large reductions (< 40,umol/100 g/min) were also observed in A:2, C:3, D:2-4 and E:3, which were areas surrounding the areas of greatest reduction. Also, several areas in the contra lateral cortex showed moderate reductions (> 70,umol/100 g/min) in LCGU ( Table 2) . Most of these areas lay in the caudal part.
Effects of oxiracetam on LCGU reduction after MCA occlusion
In the ipsilateral cortex, pretreatment with oxiracetam for 3 days dose-dependently mini mized the reduction in LCGU caused by focal cerebral ischemia after MCA occlusion (Table  1) . At the lower dose (400 mg/kg), oxiracetam minimized LCGU reductions predominantly in ischemic core areas (B:3, C:4) and their sur roundings (C:3, D:3 and 4). At the higher dose (800 mg/kg), reduction in LCGU was lessened throughout the ischemic hemisphere, especially in the ischemic center, where mean LCGU values were more than twice those in the saline-control group. The pooled values of LCGU from the ischemic center and other areas in the ipsilateral cortex typically repre sented the effects of oxiracetam at each dose (Fig. 2) .
In the contralateral cortex, LCGU reduction in the caudal part was prevented by ox iracetam at the higher dose, but oxiracetam had no effect on other areas, where no reduc tion in LCGU was shown (Table 2 ). Typical patterns of color-coded LCGU maps are shown in Fig. 3 . Table 2 . Local cerebral glucose utilization values (umol/100 g/min) in the contralateral cor tex in rats 24 hr after middle cerebral artery occlusion Fig. 2 . Effects of oxiracetam on the pooled values of local cerebral glucose utilization (LCGU) from the "ischemic center" and "other areas" in the ipsilateral cortex 24 hr after middle cerebral artery occlusion. Twenty-one areas in the ipsilateral cortex were divided into the "ischemic center" and "other areas" accord ing to the degree of reduction in LCGU in the control group, shown in Table 1 . Ischemic center: below 40 pmol/100 g/min, Other areas: above 40,umol/100 g/min. Values are means ± S.E. of 6 rats. * P < 0.05, **P<0 .01, compared with the control group (Stu dent's t-test). 0: control; 1: oxiracetam, 400 mg/kg; 
Physiological variables
Physiological variables 24 hr after MCA occlusion or sham-operation are shown in Table 3 . MCA occlusion and drug treatment had no significant effect on arterial blood pressure, blood gases (P02, PC02, pH) or hematocrit. However, blood glucose was in creased in the MCA-occluded group as com pared with the sham-operated group, and ox iracetam minimized this increase dose-depend ently. (19, 20) have demonstrated that MCA occlu sion induced LCGU reduction in rat brain. Our study confirmed the marked reduction in LCGU; however, we found that metabolic im pairment was widespread throughout the ipsi lateral cortex. The lateral part, from the fron tal to the frontoparietal cortex, generally de scribed as the ischemic center, showed the greatest reduction of LCGU following infarc tion. The change of LCGU values in the areas surrounding the ischemic center was gradual toward the caudal area, but sharp in the coronal plane. These results indicate that in an acute ischemic state, the degree of metabolic impairment is reflected by the blood supply, since the distribution and degree of LCGU reduction in the present study were similar to those of blood flow reduction in the acute state following MCA occlusion, as reported by Brint et al. (21) and Bolander et al. (22) . We found that oxiracetam pretreatment for 3 days improved the impairment of glucose metabolism induced by focal ischemia. At the lower dose of oxiracetam, this effect was seen in the areas of greatest LCGU reduction; and at the higher dose, this effect extended throughout the ipsilateral cortex. It is interest ing that improvement in the ischemic center and its surroundings preceded that in other areas. Furthermore, in several rats adminis tered oxiracetam, the infarction area was re markably minimized (T. Hokonohara et al., un published data) compared with the control group.
The chronic ischemia induced by MCA occlusion has two stages. One is the develop ing stage of ischemic brain damage, which occurs within 24-48 hr after MCA occlusion, and the other is the recovering stage, which occurs more than 48 hr after MCA occlusion (23). Kometani et al. (24) showed that ox iracetam administered for 14 days after MCA occlusion improved the disturbed circadian rhythm of spontaneous motor activity. Ox iracetam may therefore facilitate the recovery from ischemic brain damage. In the present study, we found that oxiracetam protected the brain from damage 24 hr after MCA occlu sion, and thus oxiracetam may delay the de velopment of ischemic brain damage.
Physiological variables, with the exception of plasma glucose, had no influence on brain metabolism, since these were not changed by MCA occlusion. However, the possibility ex ists that an increase in plasma glucose (hyperglycemia) is a factor that aggravates ischemic brain damage in MCA-occluded rats, as reported by Yura et al. (25) . Oxiracetam minimized the increase in plasma glucose to the same extent as it minimized LCGU reduc tion, but this effect seemed to be secondary to the protection against ischemic brain damage.
Nowicki et al. (13) noted that decreases in ATP concentration in the neocortex were in duced by focal cerebral ischemia 2-48 hr after MCA occlusion in rats. Their findings indicate the importance of the influence of energy fail ure in the ischemic brain. Piracetam, the pro totype of pyrrolidone derivatives (which in clude oxiracetam), has been shown to enhance adenylate kinase activity (26) and the synthesis and/or turnover of cytochrome b5 (27) . Thus, enhancement of ATP synthesis and mito chondrial function may be a result of the pro tective effect of oxiracetam on ischemic brain damage observed in this experiment.
Oxiracetam has been shown to stimulate high affinity choline uptake in the rat hippo campus (5) and to prevent the decrease in brain acetylcholine level brought about by electroshock (4) and scopolamine (2) in rats. These findings suggest that oxiracetam en hances brain cholinergic mechanisms. Al though it is not clear whether cholinergic mechanisms influence the functional and meta bolic damage seen in the ischemic brain, Scre min and Jenden (14) have observed that the synthesis and release of acetylcholine in the neocortex were impaired by focal cerebral ischemia in rats, and Weinberger et al. (28) have reported that scopolamine induced a de crease in LCGU in rats. It is possible that the protective effects of oxiracetam on LCGU re duction in focal cerebral ischemia are due, in part, to an increase in the activity of brain cholinergic mechanisms.
In the contralateral cortex, a significant re duction in LCGU occurred; this was moderate compared with that occurring in the ipsilateral cortex and was observed mainly in the caudal areas. However, since the cerebral blood flow was well maintained in the contralateral cor tex, except during the acute phase, it was not possible that this reduction in LCGU was due to failure in blood flow. We therefore consi dered this phenomenon to be one of "transcal losal diaschisis", which has been described by Feeney and Baron (29) , and observed by Ginsberg et al. (30) in cats and Kataoka et al. (18) in rats. The question of why "diaschisis" was observed mainly in caudal areas then arose. An explanation might be provided by Sokoloff (31) , who found that decreases in functional activity resulted in reduced rates of glucose utilization and that these effects were particularly striking in the visual and auditory systems of the rat. Oxiracetam at the higher dose also improved LCGU reduction due to diaschisis in the caudal areas of the contra lateral cortex. We considered that this im provement might have partly depended on the recovery of LCGU in the ipsilateral cortex partly on the direct action of oxiracetam. Ox iracetam had protective effects throughout the areas that showed reductions in LCGU, but had no influence in areas that had normal LCGU values. This suggests that oxiracetam plays a role in preserving metabolic systems in the ischemic brain, but does not act as an acti vator or an inhibitor in the normal brain.
It has been shown by Satoh et al. (7, 8) that the effects of pyrrolidone derivatives are char acterized by a bell-shaped concentration re sponse curve. However, the pharmacological properties of oxiracetam differ depending on the dose used. At lower doses, oxiracetam en hances neuronal transmission (in vitro dose: 10-6 -10-7 M) (6) and facilitates memory and learning in mice (in vivo dose: 10-50 mg/kg) (1). At higher doses, moderate and transient cerebral impairment is improved (in vivo dose: 50 300 mg/kg) (2, 4) . Furthermore, in the present study, we found that oxiracetam mini mized severe ischemic metabolic damage (in vivo dose: 400-800 mg/kg). These findings show that oxiracetam may have two distinct characteristics that can be useful in the treat ment of cerebrovascular dementia.
